# Short-term Use of Dapagliflozin to Protect Kidney Function in CKD Patients

> **NCT05225077** · PHASE4 · UNKNOWN · sponsor: **Dong-A University** · enrollment: 600 (estimated)

## Conditions studied

- Renal Insufficiency, Chronic
- Cardiac Catheterization
- Percutaneous Coronary Intervention

## Interventions

- **DRUG:** Dapagliflozin 10 MG [Farxiga]

## Key facts

- **NCT ID:** NCT05225077
- **Lead sponsor:** Dong-A University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-01
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2022-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05225077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05225077, "Short-term Use of Dapagliflozin to Protect Kidney Function in CKD Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05225077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*